Permira Funds and the Marcucci family complete investment in Kedrion & BPL
Announced appointment of Ugo Di Francesco as CEO
Kedrion Biopharma Recognized for Innovation in Treating Rare Disease
RYPLAZIM® is the first FDA Approved Treatment for Plasminogen Deficiency Type 1
Kedrion Biopharma Extends Contract Manufacturing Agreement (CMA) for GAMMAKED in the US, Ensuring Availability to Patients
Kedrion Biopharma will continue to market and distribute GAMMAKED in the U.S. through end of 2025
Kedrion Biopharma to commercialize RYPLAZIM® in U.S
RYPLAZIM® (plasminogen, human-tvmh) will address needs in patients with ultra-rare condition Plasminogen Deficiency Type 1
Kedrion grows in North America as it completes acquisition of Prometic
Launch is planned for the first ever FDA-approved treatment for patients suffering from Congenital Plasminogen Deficiency
Kedrion and Kamada Announce FDA Approval of KEDRAB® Label Update
KEDRAB® is now the first and only HRIG available in the U.S. to be clinically studied in children
First patient enrolled in KIDCARES10
Kedrion Biopharma Pediatric Primary Immunodeficiency Study
Kedrion Biopharma Phase III Trial, CARES10, achieves important milestone
Kedrion Biopharma, an international biopharmaceutical company specialized in the manufacture and distribution of plasma-derived therapeutic products used in treating rare and serious diseases.
A chat with Val Romberg
A question and answer session with the recently appointed CEO of Kedrion, Val Romberg: his first impressions of the company, his views on growth potential, and his reflections on Kedrion’s commitment to developing new anti COVID-19 therapies.